News | May 20, 2015

Data Show Remote Monitoring Technologies Significantly Lower Healthcare Costs, Hospitalizations

St. Jude Medical study finds remote monitoring cuts 10 hospitalizations, 119,000 hospital days and more than $370,000 per 100 patients

St. Jude Medical, Merlin, remote monitoring, lower costs, hospitalizations, HRS

May 20, 2015 — New data from St. Jude Medical found that patients with cardiac devices who use remote monitoring have significantly fewer hospitalizations and lower overall healthcare costs than patients who do not. The data was presented during a late-breaking clinical trial session during Heart Rhythm 2015, the Heart Rhythm Society’s annual scientific sessions. The findings were a result of a five-year study, one of the largest to date on remote monitoring technologies.

“This study is the first of its kind to find an economic benefit when remote monitoring is utilized in pacemaker, defibrillator and cardiac resynchronization patients in the U.S.,” said Jonathan Piccini, M.D., associate professor of medicine at Duke University Medical Center in Durham, North Carolina. “Use of remote monitoring is associated with lower risks of hospitalization, shorter hospital stays, and lower rates of heart failure and stroke hospitalization. Additionally, since fewer than half of cardiac device patients currently use remote monitoring, our findings suggest a significant opportunity for quality improvement. These important observations should have significant implications for patient management, as well as costs to the healthcare system.”

The study, which obtained data from a real-world setting, reinforces the important role of remote monitoring in improving the overall care of patients treated with implantable cardiac devices. Researchers analyzed data from more than 90,000 patients with pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. The data showed that remote monitoring with systems, such as the St. Jude Medical Merlin.net Patient Care Network (PCN), eliminates 10 hospitalizations and 119 hospital days and resulted in cost savings of more than $370,000 per 100 patients annually.

The findings offer additional evidence of the benefits of remote monitoring. In a study presented at last year’s Heart Rhythm Society meeting, and recently published in the Journal of the American College of Cardiology, St. Jude Medical found improved survival rates of patients using the company’s Merlin.netPCN. Patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring. High adherence was measured as weekly transmissions of patient data from the [email protected] transmitter to the Merlin.net PCN at least 75 percent of the time. Recommendations for remote monitoring technologies were recently updated and published by the Heart Rhythm Society.

“Recent data surrounding remote monitoring technologies have been important to advancing the understanding of the benefits these systems provide,” said Niraj Varma, M.D., electrophysiologist at the Cleveland Clinic in Cleveland, OH. “The updated recommendations announced recently by the Heart Rhythm Society reflect the findings from these important studies and highlight the importance of using remote monitoring systems to improve the consistency of follow-up care for patients. We will continue to work with industry to further reinforce how utilization of the remote monitoring systems can improve clinical outcomes for patients around the world.”

For more information: www.sjm.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init